Somatic Cancer Genetics in the UK: Results from Phase One of the Cancer Research UK Stratified Medicine Programme

Lindsay CR, Shaw EC, Hall G, Brenton J, Evans TRJ, Newton-Bishop J, Mason MD, Morton D, Oien KA, Harrison DJ, Hanby AM, Blackhall F, Nicholson AG, Johnson PWM.

ESMO Open: accepted for publication.


KRAS: reasons for optimism in non-small cell lung cancer

Lindsay CR, Jamal-Hanjani M, Forster M, Blackhall F

Eur J Cancer: in press.


SELECT-3: a phase I study of the MEK1/2 inhibitor selumetinib in combination with first-line chemotherapy regimens for NSCLC

Dean E, Steele N, Arkenau T, Blackhall F, Haris NM, Lindsay CR, Saggese M, Califano R, Greystoke A, Voskoboynik M, Ghiorghiu D, Dymond A, Smith I, Plummer R

Br J Cancer: 2017; 117:938-946.


A Prospective Examination of Circulating Tumor Cell Profiles in Non-Small Cell Lung Cancer Molecular Subgroups

Lindsay CR, Faugeroux V, Michiels S, Pailler E, Facchinetti F, Bluthgen MV, Pannet C, Ngo-Camus M, Bescher G,  Caramella C, Billiot F, Remon J, Planchard D, Soria J-C, Farace F, Besse B

Ann Oncol: 2017; 28:1523-1531.


Circulating Tumor Cells with Aberrant ALK-Copy Number Predicts Progression-Free Survival to Crizotinib in ALK-Rearranged Non-Small-Cell Lung Cancer Patients 

Pailler E, Oulhen M, Borget I, Remon, J, Ross K, Auger N, Billiot F, Ngo-Camus M, Commo F, Lindsay CR, Planchard D, Soria JC, Besse B, Farace F

Cancer Res: 2017; 77(9):2222-2230.


CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies

Remon J, Abedallaa N, Taranchon-Clermont E, Bluthgen V, Lindsay CR, Besse B, Thomas de Montpréville V

Lung Cancer: 2017; 108: 168-172.


Book Chapter: ‘Stratified Medicine in the UK’

Lindsay CR, Shaw E, Johnson PWM

‘Precision Oncology’ publication for the Association of Cancer Physicians: 2017.


Method for semi-automated microscopy of filtration-enriched circulating tumor cells

Pailler E, Oulhen M, Billiot F, Galland A, Auger N, Faugeroux V, Laplace-Builhé C, Besse B, Loriot Y, Ngo-Camus M, Hemanda M, Lindsay CR, Soria JC, Vielh P, Farace F

BMC Cancer: 2016; 16: 477



Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network

Remon J, Girard N, Mazières J, Dansin E, Pichon E, Biemar J, Dubos C, Lindsay CR, Besse B

Lung Cancer: 2016; 97: 99-104


Thymic malignancies: Moving forward with new therapeutic strategies.  

Remon J, Lindsay CR, Bluthgen MV, Besse B

Cancer Treatment Rev: 2016; 46: 27-34


Vimentin and Ki67-expression in circulating tumor cells derived from castrate-resistant prostate cancer

Lindsay CR, Le Moulec S, Billiot F, Loriot Y, Ngo-Camus P, Vielh P, Fizazi K, Massard C, Farace F

BMC Cancer: 2016; 16:168


The potential diagnostic power of circulating tumor cell analysis for non-small cell lung cancer

Ross K , Pailler E, Faugeroux V, Taylor M, Oulhen M, Auger N, Planchard D, Soria JC, Lindsay CR, Besse B, Vielh P, Farace F

Expert Rev Mol Diag:  2015; 15: 1605-29


High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer

Pailler E, Auger N, Lindsay CR, Vielh P, Islas-Morris-Hernandez A, Borget I, Ngo­-Camus M, Planchard­­ D, Soria J-C, Besse B, Farace F

Ann Oncol: 2015; 26(7):1408-15


A long-term spinal intra-medullary response to ceritinib in ALK rearranged non-small-cell lung cancer

Biya J, Caramella C, Planchard D, Lindsay CR, Besse B

J Thorac Oncol: 2015; 10(6): e44-5


Lessons for molecular diagnostics in oncology from the Cancer Research UK Stratified Medicine Programme

Lindsay CR, Shaw E, Walker I, Johnson PWM

Expert Rev Mol Diag: 2015; 15(3):287-9


Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of other cancers

Lindsay CR, Spiliopolou P, Waterston A

Ther Adv Med Oncol: 2015; 7(2): 107-21


A phase I dose escalation study of OSI-906 in patients with advanced solid tumours

Puzanov I, Lindsay CR, Goff L, Sosman J, Gilbert J, Berlin J, Poondru S, Simantov R, Gedrich R, Stephens A, Chan E, Evans TRJ.

Clin Cancer Res: 2015; 21(4): 701-11


A Rac-independent role for P-Rex1 in proliferation

Lindsay CR, Campbell AD, Faller WJ, Cuesta N, Ozanne B, Sansom OJ

Journal Invest Dermatol: 2015;135(1): 314-8


Melanoma cells make LPA gradients that drive their chemotactic dispersal and invasion

Muinonen-Martin AJ, Zhang Q, Faller W, Moyes C, Drummond A, Susanto O, Veltman D, Kalna G, Lindsay CR, Bennett DC, Sansom OJ, Herd R, Jones R, Machesky LM, Wakelam MJO, Knecht DA, Insall RH.

PLoS Biology: 2014;12(10): e1001966


What is the optimal use of cetuximab in first line treatment of metastatic colorectal cancer?

Lindsay CR, Roxburgh P, Graham J

Future Oncology: 2013; 9(6): 825-9


P-Rex1 is required for efficient melanoblast migration and melanoma metastasis in mice

Lindsay CR, Lawn S, Campbell AD, Faller W, Mort RL, Jackson IJ, Ridgway RA, Morton JP, Doyle B, Gallacher WM, Rafferty M, Murphy IG, McDermott EW, Sheahan K, Hegarty S, Van Kempen L, Beermann F, Larue L, Der C, Welch H, Ozanne B, Sansom OJ

Nature Comms: 2011; 2: 555

‘Dermatologyblog’ online interview:


Rac1 drives melanoblast organization during mouse development by orchestrating pseudopod-driven motility and cell cycle progression

Li A, Ma Y, Yu X, Mort R, Lindsay CR, Insall RH, Chernoff J, Snapper SB, Tybulewicz V, Jackson I, Larue L, Sansom O, Machesky LM

Dev Cell: 2011; 21(4): 722-34


XELOX in colorectal cancer: a convenient option for the future?

Lindsay CR, Cassidy J

Expert Rev Gastroenterol Hepatol: 2011; 5(1): 9-19


Adjuvant treatment of breast cancer in post-menopausal women: role of Exemestane                                                            

Macpherson IRJ, Lindsay C, Canney P

Breast Cancer – Targets and Therapy: 2010; 2: 59-70


Current status of cediranib: the rapid development of a novel anti-angiogenic therapy                                                                

Lindsay CR, MacPherson IR, Cassidy J

Future Oncology: 2009; 5(4): 421-32


Recombinant human epoetin beta in the treatment of chemotherapy-related anemia

MacPherson IR, Lindsay CR, Reed N

Therapeutics & Clinical Risk Management: 2009; 5(1): 261-70


Targeting insulin growth factor receptors: a potential novel anti-cancer therapy

Lindsay CR, Evans TRJ

Biologics: 2008; 2(4): 855-864